Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 86 of 86 entries
View as:

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01740089 Org: User:
Start: 11/30/11 End: 12/31/13 Due: 12/31/14

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03912389 Org: User:
Start: 06/01/19 End: 12/31/23 Due: 12/31/24

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02727907 Org: User:
Start: 02/12/15 End: 08/11/17 Due: 08/11/18

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03472027 Org: User:
Start: 10/02/17 End: 12/04/18 Due: 12/04/19

Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01759030 Org: User:
Start: 12/31/12 End: 07/31/15 Due: 07/31/16

Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT02506868 Org: User:
Start: 08/08/15 End: 12/21/17 Due: 12/21/18

DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

Phase: N/A Priority: Normal
NCT ID: NCT04811443 Org: User:
Start: 01/12/21 End: 06/12/22 Due: 06/12/23

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03390101 Org: User:
Start: 12/26/17 End: 01/20/22 Due: 01/20/23

Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Phase: N/A Priority: Normal
NCT ID: NCT06640530 Org: User:
Start: 03/21/24 End: 03/31/27 Due: 03/31/28

Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06715540 Org: User:
Start: 03/29/24 End: 12/31/25 Due: 12/31/26

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

Phase: N/A Priority: Normal
NCT ID: NCT03912415 Org: User:
Start: 10/01/19 End: 12/01/24 Due: 12/01/25